Company News Summary | 25 Nov 2019
Click the print icon in your browser to print this report. Currency is in AUD unless otherwise specified
Avita Medical Enters into Collaboration to Explore Potential Spray-On Treatment of Genetically Modified Cells for Epidermolysis Bullosa
09:21:00 | Associate analysts
Original annuncemenet:AVITA Medical, CU Denver Announce Preclinical Collaboration
Avita Medical announced a preclinical research collaboration to establish proof-of-concept and explore further development of a spray-on treatment of genetically modified cells for patients with epidermolysis bullosa (EB), with potential applicability to other genetic skin disorders. The partnership will pair its patented and proprietary Spray-On Skin Cells technology and expertise with the Gates Center's innovative, patent pending combined reprogramming and gene editing technology to allow cells to function properly. Under the terms of the Sponsored Research Agreement (SRA), it will retain the option to exclusively license technologies emerging from the partnership for further development and commercialization.
|This report appeared on www.morningstar.com.au||2020 Morningstar Australasia Pty Limited|
© Copyright 2020 Morningstar Australasia Pty Ltd ABN: 95 090 665 544 ("Morningstar"), AFSL no 240892. (a subsidiary of Morningstar, Inc.). This information is to be used for personal, non-commercial purposes only. No reproduction is permitted without the prior written content of Morningstar. Some of the material provided is published under licence from ASX Operations Pty Limited ACN 004 523 782 ("ASXO").